Health·Agência Brasil·5d agoBrazil
Brazil Approves First Human Trial of Vivaxin Malaria Vaccine
Anvisa clears tests for 100% Brazilian-made Plasmodium vivax shot
Positive1 min readImportance
AI Summary
Brazil's Anvisa authorized the first human trial of Vivaxin, a 100% Brazilian vaccine against Plasmodium vivax malaria, with R$ 12 million in federal funding for Phase I-III clinical trials.
Keywords
malaria vaccineVivaxinAnvisaclinical trialsBrazil
/2026/01/14/montage-photo-1-696814730292a233985880.png)